← Insider Monitor
Pasithea Therapeutics Corp. logo
KTTA

Pasithea Therapeutics Corp.

Nasdaq · Pharmaceutical Preparations

3
Insider trades
0
Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

Pasithea Therapeutics Corp. is a biotechnology company developing drug therapies for neurological and psychiatric disorders, including ketamine-based intravenous infusion treatments and small-molecule compounds targeting conditions such as depression and autoimmune disease. The company also operates a drug discovery business supporting its internal pipeline and external research programs.

Industry
Pharmaceutical Preparations
Headquarters
Miami Beach, FL
Exchange
Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

InsiderTypeValueDate
Coastlands Capital LP10% OwnerBuy$411KNov 17, 2026
Coastlands Capital LP10% OwnerBuy$291KNov 16, 2026
Coastlands Capital LP10% OwnerBuy$104KNov 13, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for KTTA.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable KTTA activity by email

Free alerts for the insider and congressional trades worth watching.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.